Ultragenyx Pharmaceutical Inc. Earnings

Ultragenyx Pharmaceutical Inc.’s revenue jumped 25.55% since last year same period to $207Mn in the Q4 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 29.43% jump in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit jumped 3.29% since last year same period to $-129Mn in the Q4 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 28.5% jump in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 22.97% since last year same period to -62.32% in the Q4 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 44.76% jump in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.34 - a -16.52% fall from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.34.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.